Articles tagged with Antibodies
Researchers at UCI have found a new diagnostic tool for multiple sclerosis by detecting increased levels of antibodies that inhibit energy production in neurons. This breakthrough could lead to earlier and more effective treatment for the chronic disease.
Researchers discovered a non-human sialic acid sugar in biotech drugs that can provoke a strong immune response in some individuals, worsening chronic inflammation. A simple modification to the drug-making process could solve this problem by adding human sialic acid.
Researchers at UT Southwestern Medical Center discovered a link between anti-TPO antibodies and placental abruption in pregnant women. The study of over 17,000 women found that antibody-positive women were three times as likely to experience placental separation during labor.
A novel microfluidic HIV test developed by Prof. Alexander Revzin uses antibodies to 'capture' white blood cells called T cells affected by HIV. The test detects the types and levels of inflammatory proteins released by the cells, providing six parameters simultaneously from a small blood sample.
A molecule that binds toll-like receptors doubles the early antibody response to an antigen and shifts it to a more effective IgG form. The findings support bridge immunity, which links innate and adaptive arms of the immune response.
UCI chemists develop synthetic antibodies that block bee venom by encasing melittin, a peptide causing cells to rupture. These 'plastic antibodies' offer a promising alternative to natural antibodies for treating medical conditions, with potential applications in fighting deadly toxins and pathogens.
The US Department of Defense has awarded over $1 million to a team of researchers at the University of Western Ontario to develop an antibody treatment for spinal cord injuries. The therapy targets inflammation caused by CD11d protein, which can limit damage and improve recovery rates.
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
Researchers at Stanford University School of Medicine have discovered that antibodies are critical to the repair of nerve damage in the peripheral nervous system. In a new study, scientists show that certain antibodies can facilitate myelin clearance and nerve regeneration, while others do not.
Researchers have successfully tested a plastic antibody that mimics natural antibodies in the bloodstream of living mice, demonstrating its ability to recognize and fight infectious substances. The breakthrough could lead to medical applications for custom-tailored nanoparticles to combat various antigens.
Researchers at Fox Chase Cancer Center are testing a new antibody, MM-111, that targets the HER2/HER3 pathway in patients with advanced breast and gastric cancers. The trial aims to provide an additional therapeutic target within the HER2 pathway and potentially overcome resistance to current HER2-targeted therapies.
Research suggests that exposure to herpes simplex virus 1 may contribute to cognitive and brain abnormalities in schizophrenia. Patients with antibodies for HSV-1 performed poorly on cognitive tests and had reduced brain volume in key regions, including the anterior cingulate and cerebellum.
Researchers have developed silica cages that can package anti-cancer antibodies, which significantly slow the growth of tumors and prolong the lives of mice. The treatment also reduces side effects compared to traditional intravenous drips.
Researchers at Arizona State University have developed a method to create synthetic antibodies that can bind with human proteins with high affinity and specificity. This technique, called synbody construction, involves combining random amino acid sequences to form a binding molecule that can target specific proteins.
A new study reveals that the human immune system's defences against dengue fever can actually help the virus infect more cells. This finding could lead to the development of an effective vaccine by avoiding certain antibodies produced in response to the virus.
A study analyzing blood samples from Singapore found significant variation in H1N1 infection risks among different age groups and military personnel. Younger individuals and those with household members who seroconverted had higher infection rates, emphasizing the need for tailored interventions.
A new study found that smoking increases MS risk in individuals with high levels of Epstein-Barr virus antibody, but not those without it. The research suggests a link between smoking, immune response to the virus, and MS development.
Researchers at Duke University Medical Center have discovered a set of naturally occurring antibodies that can block HIV's entry into certain blood cells. These polyreactive anti-phospholipid antibodies show promise as a potential new strategy for HIV vaccine design.
A genetically modified tobacco plant can produce antibodies to toxic MC-LR, rendering it harmless. This innovative technology could serve as a major tool in keeping water sources safe in developing nations.
Scientists at Emory University School of Medicine discovered a set of bacteria-killing proteins that recognize human blood type molecules on bacterial surfaces. These proteins, galectin-4 and galectin-8, can kill certain strains of E.coli within minutes.
A retrospective study of Red Cross donor and hospital data found that patients receiving female-donor plasma had better lung function, reduced risk of death within 30 days of surgery, and longer hospital stays compared to those who received male-donor plasma.
Research from Malawi and the UK reveals a two-pronged immune response that could combat even the most resilient strains of nontyphoidal Salmonella. Protective antibodies have been identified that recognize bacteria in the blood and kill them without immune cell help, offering hope for an effective vaccine.
Scientists have created antibodies in llamas to detect seven types of botulinum neurotoxins, which are highly toxic and can cause paralysis. These llama antibodies, called single domain antibodies, may play a role in future anti-botulism treatments and could improve biosensors for detecting toxins.
Research synthesizes data from various studies on anti-merozoite antibody responses and their link to protection against clinical malaria. Merozoite antigens are key targets of protective immunity, with antibodies to MSP-3, MSP-119, and AMA1 offering substantial protection.
Galapagos finches develop antibodies against two parasites that invaded the islands, suggesting they can fight off alien invaders. The immune system recognizes these parasites and produces specific antibodies, which may help the birds resist the threats.
Researchers at Boston Children's Hospital have discovered a gene enhancer responsible for activating cancer-causing genes in B cells, leading to the development of a new target for lymphoma therapy. The study suggests that targeting this regulatory component could potentially arrest lymphomas and other blood-related cancers.
Research from the University of Rochester Medical Center found that using common pain killers like Advil and Tylenol at the time of flu injection can blunt the vaccine's effect. The study suggests that timing and dosage of pain relievers also play a role in reducing antibody production, which is necessary for immune protection.
Researchers found that high-affinity mutant viruses alternate with low-affinity forms in antigenic drift. Increasing child vaccination could slow this process and extend seasonal influenza vaccine effectiveness.
Researchers at the Oklahoma Medical Research Foundation have made a groundbreaking discovery that could help treat traumatic injuries and severe diseases. They found an antibody that can counteract histones' deadly effects on blood vessels, potentially preventing uncontrolled bleeding and fluid buildup.
A study found that high transglutaminase antibody levels can accurately diagnose mucosal atrophy in celiac disease, making duodenal biopsy unnecessary. The predictive value of tTG antibodies may vary by age, with higher accuracy in adults than children.
Researchers at Stanford University developed a new magnetic-nano sensor chip that can detect cancer-associated proteins with high accuracy and search for up to 64 different proteins simultaneously. The sensor is up to 1,000 times more sensitive than current methods and can detect biomarkers in bodily fluids with low concentrations.
Researchers at the Monell Chemical Senses Center discovered that oleocanthal alters the structure of neurotoxic beta-amyloid proteins, impairing their ability to damage brain nerve cells. This structural change makes oleocanthal a potential target for developing effective immunotherapy treatments.
Researchers at Ohio State University have identified B cells as a key player in worsening spinal cord injury outcomes, but also found that removing or inhibiting these cells may help improve recovery. The study suggests potential new therapeutic targets for minimizing injury and promoting repair after traumatic spinal cord injury.
A new study by neuroscientists at Ohio State University suggests that immune responses to spinal cord injuries may actually worsen and extend the damage. Inhibiting antibody-producing B cells may promote healing and reduce long-term effects of spinal cord injury.
Anti-glycan antibodies are found to be a common feature of celiac disease at diagnosis, linked to severe malabsorption, and lost after long-term gluten-free diet. The presence of these antibodies is not associated with NOD2/CARD15 mutations.
Researchers at Columbia University's Mailman School of Public Health have found a link between antibodies to strep throat bacteria and the development of obsessive-compulsive disorder in mice. The study suggests that an inappropriate immune response to the bacteria may trigger psychiatric symptoms, providing new insights into identifyi...
Researchers are exploring the use of anti-growth factor drugs to treat children's eye diseases, offering a new tool in the fight against vision loss. However, specialists warn that these drugs may pose serious side effects, particularly in young patients.
Patients with systemic lupus erythematosus (SLE) exhibit diminished immune responses to the flu vaccine, including lower antibody and cell-mediated responses. The study found that vaccination did not induce disease activity, but may increase morbidity and mortality due to influenza infection in these patients.
Glioblastoma, the deadliest form of brain cancer, has shown promise in treating with an engineered antibody that shuts down tumor growth. Researchers at Lombardi Comprehensive Cancer Center successfully tested the antibody in human cells and animal studies.
Researchers have developed an in-vitro antibody production technique to detect HIV infection earlier, reducing the diagnostic window period. This method promotes the synthesis and release of antibodies against HIV-1 prior to detection in plasma samples, leading to safer blood supply and improved diagnosis.
Researchers at La Jolla Institute have discovered the specific gene that triggers antibody production, a key step in mounting an immune response against viruses and pathogens. The finding has significant implications for developing new and more effective vaccines.
Researchers create highly stable chemical compounds that can bind to proteins with high affinity and selectivity, replacing traditional antibodies used in medical diagnostic tests. The technique involves a stepwise approach using in situ click chemistry, allowing for the creation of complex molecules in a relatively simple process.
A new study conducted by an Irish-led research team found no link between folic acid-related auto-antibodies and the risk of having a child with spina bifida. The study, which involved over 140 mothers of affected children, confirms previous findings that maternal folate status can prevent neural tube defects.
Dr. Jay Kolls receives $1.8M grant to explore antibody responses against Pneumocystis fungus, aiming to develop a vaccine to prevent or treat PCP. Preliminary studies show that carbohydrate antibodies participate in early clearance and regulate long-term immune responses.
Researchers found that HIV-1 damages the gut's B-cell arm of the immune system just days after transmission, disrupting its ability to fight infections. This damage affects both reactive and non-reactive B cells, leading to a weak response against pathogens like influenza.
Dr. Keri Smith has received a Career Development Award from the National Hemophilia Foundation to develop a therapy for people with Hemophilia A. Her approach involves altering chemical signals produced by T cells that trigger immune responses, making individuals more receptive to replacement Factor VIII.
Scientists have identified PLA2R, a protein found in normal human glomeruli, as the target antigen in idiopathic membranous nephropathy. This discovery holds promise for developing a blood test to replace kidney biopsies and determining which patients are most likely to benefit from immunosuppressive treatment.
A new computer model developed at MIT allows researchers to design more stable antibodies, reducing clumping and aggregation issues. The model identifies regions responsible for aggregation and enables mutation of amino acids to increase stability without affecting function.
A study of 115 young women with iron deficiency anemia found that serological screening for H. pylori and celiac disease increased gastroscopy compliance rates. The tests were confirmed by gastroscopy, which identified IDA-related GI causes in most cases.
A new device has been developed that can detect viruses and biological materials more quickly and cheaply than existing methods. The device uses synthetic antibody mimic proteins attached to nanowires to create a sharp measurement of current, allowing for rapid detection in under 10 minutes.
A new multimeric-L2 protein vaccine shows robust antibody responses and protection against human papillomavirus (HPV) infection in mice and rabbits. The vaccine has the potential to address the limited protection of current HPV vaccines against other HPV types, which cause cancer.
Researchers found that antibody interference can hinder vaccine effectiveness, proposing a new approach to design more powerful vaccines. They suggest intentionally developing a vaccine strain that differs from the anticipated infectious virus at specific sites.
A study of over 8,000 people found that higher blood levels of folic acid were associated with fewer reported allergies, less wheezing, and a lower likelihood of asthma. The researchers recommend further studies to confirm their results and establish safe doses.
Researchers have developed an engineered antibody called DTA-1 that helps the immune system overcome its natural reluctance to attack tumor cells. In a mouse model of melanoma, DTA-1 led to rejection of 50-60% of tumors by impairing regulatory T cells, providing new hope for improved cancer treatment options.
A team of researchers developed an antibody targeting FGFR3, which showed potent antitumor activity against human bladder cancer cells and t(4;14)-positive multiple myeloma cells. The antibody also demonstrated activity against normal FGFR3 and mutated forms associated with cancer.
Researchers have developed a new yogurt that fights stomach ulcer bacteria with almost vaccine-like effects. The yogurt contains an antibody that reduces bacterial activity, offering a potential alternative to antibiotics for treating gastritis and stomach ulcers.
Researchers at Rockefeller University have identified a diverse team of antibodies in slow-progressing HIV patients whose coordinated pack hunting knocks down the virus. These natural antibodies, produced by six people infected with HIV, show limited neutralizing ability when alone but become effective when combined.
Researchers at the University of Liverpool have determined the atomic structure of the binding between an antibody and a brain protein that could be key to treating vCJD. The study found that this antibody, ICSM18, has therapeutic potential in preventing brain cell infection and reversing early damage caused by the disease.
A new immune-system 'atlas' will improve doctors' ability to monitor transplanted organs and shed light on the mechanisms of gradual, cumulative kidney malfunction after transplant. The atlas allows for inexpensive, noninvasive blood tests that show whether a donated kidney is infected or accruing chronic injuries.
Researchers found significant correlations between serum levels of anti-tTG IgA and anti-DGP antibodies in untreated celiac disease patients. The study suggests an immune response difference to deamidated gliadin and tissue transglutaminase, supporting the hapten-carrier theory for anti-tTG IgA origin.